Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07002905 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
A Phase 2 study, sponsored by Ascletis Pharma (China) Co., Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
NCT07002905 is a Phase 2 study that has completed, run by Ascletis Pharma (China) Co., Limited. The registered enrollment target is 125 participants.
The verdict
NCT07002905, a Phase 2 study, has completed, sponsored by Ascletis Pharma (China) Co., Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.
Interventions
- DRUG ASC30 tablets or ASC30 tablets A1 or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-07-03 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07002905
The ClinicalTrials.gov registry entry for NCT07002905 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascletis Pharma (China) Co., Limited, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASC30 tablets or ASC30 tablets A1 or placebo is the first listed.
NCT07002905 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07002905 about?
NCT07002905 is a clinical study titled "A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities". This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.
What is the current status of trial NCT07002905?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2025-07-03. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT07002905?
The interventions under investigation include: ASC30 tablets or ASC30 tablets A1 or placebo (DRUG).
Who is sponsoring clinical trial NCT07002905?
This trial is sponsored by Ascletis Pharma (China) Co., Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.